Date:5/5/2011

ssions. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to,   continued acceptance of the Company's products in the marketplace, the effect of global economic conditions on the ability and willingness of customers to purchase our systems and the timing of such purchases, competitive factors, changes resulting from the recently enacted healthcare reform in the U.S., including changes in government reimbursement procedures, dependence upon third-party vendors, timing of regulatory approvals, and other risks discussed in the Company's periodic and other filings with the Securities and Exchange Commission. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release. There can be no assurance that the Company will recognize revenue related to its purchase orders and other commitments in any particular period or at all because some of these purchase orders and other commitments are subject to contingencies that are outside of the Company's control. In addition, these orders and commitments may be revised, modified, delayed or canceled, either by their express terms, as a result of negotiations, or by overall project changes or delays.

'/>"/>

SOURCE Stereotaxis, Inc. Copyright©2010 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4
Related medicine technology :

1. Stereotaxis Continued Leadership in Scientific Outcome Data Prominently Displayed with Multiple Key Presentations at HRS 2011
2. Stereotaxis Reports First Quarter 2011 Financial Results
3. Stereotaxis Introduces New Electrophysiology Platform: Epoch™
4. Stereotaxis to Present at Upcoming Investor Conferences
5. Stereotaxis Reports 2010 Financial Results, Provides 2011 Financial Outlook
6. Stereotaxis Announces First Worldwide Use of Remote Magnetic Navigation for Renal Ablation to Treat Hypertension
7. Stereotaxis to Report Fourth Quarter and Full Year 2010 Financial Results and Conduct Conference Call on February 28, 2011
8. Stereotaxis Announces CE Mark and First Human Case for Vdrive™
9. Stereotaxis Announces Expansion of Catheter Strategic Partnership
10. Stereotaxis Announces Global Initial Training Site at University of Chicago
11. Stereotaxis Completes $40 Million Credit Facility